Home / Innere Medizin / Onkologie / Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

Excellent news for patients who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today by Dr Jeffrey Weber.

Interviewpartner:

Redaktion:

Produktion:

Excellent news for patients who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today by Dr Jeffrey Weber, deputy director, Perlmutter Cancer Center, NYU Langone Health, New York, USA, at the ESMO 2017 Congress in Madrid.The planned interim analysis was done  after a minimum follow-up of 18 months. It proofed to be effective across all prespecified subgroups of patients.

LOGIN

Login

Passwort vergessen?